Charles River opens Shanghai preclinical facility
To support the growing demand from multinational pharmaceutical clients for outsourced drug development services, Charles River Laboratories International has opened its 60,000ft2 preclinical facility in Shanghai.
To support the growing demand from multinational pharmaceutical clients for outsourced drug development services, Charles River Laboratories International has opened its 60,000ft2 preclinical facility in Shanghai.
The new facility is expected to provide Good Laboratory Practice (GLP) services in the first quarter of 2009.
In addition, it will provide a wide range of services that are compliant with leading regulatory agencies including:
- Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC),
- Canadian Council on Animal Care (CCAC),
- China's State Food and Drug Administration (SFDA),
- Organisation for Economic Cooperation and Development (OECD); and
- US Food and Drug Administration (FDA).
"As our clients make their initial forays into China, we are creating a centre of excellence that embodies global best practices alongside them," said James C. Foster, president, chairman and ceo of Charles River. "The same high standards of research, safety, humane care and good laboratory practices that globally distinguish Charles River are replicated in our Shanghai facility.
"Expanding into this arena is a marathon "¢ not a sprint "¢ and this facility marks the first step in our journey.’
In March 2007, Charles River announced a joint venture with Shanghai BioExplorer Co. Ltd, a Shanghai-based provider of preclinical services, to form Charles River Preclinical Services Greater China. The joint venture is majority owned and controlled by Charles River.